Amgen Announces New Data Being Presented At ASH 2021

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rd American Society...

Related Keywords

Serbia ,Kazakhstan ,Qatar ,Australia ,Taiwan ,Ayas ,Lima ,Peru ,United States ,Hong Kong ,Belarus ,Brazil ,Russia ,Woman ,Bahrain ,Mexico ,New Zealand ,India ,Egypt ,Morocco ,Kuwait ,Ecuador ,Switzerland ,Georgia ,Malaysia ,Japan ,Philippines ,Algeria ,Argentina ,Atlanta ,Philadelphia ,Pennsylvania ,Lebanon ,Colombia ,United Arab Emirates ,Canada ,Jordan ,Puerto Rico ,Thailand ,Israel ,Singapore ,Saudi Arabia ,Chile ,Turkey ,Macao ,Macau General ,Macau ,America ,American ,Megan Fox ,Trish Rowland ,Jakubowiaka Semin Hematol ,Davidm Reese ,Kyowa Kirin Co Ltd ,Amgen ,Pregnancy Surveillance Program ,Drug Administration ,York Heart Association Class ,Beigene Ltd ,Data Monitoring Committee ,American Society Of Hematology ,Exchange Commission ,Therapeutics Inc ,European Union ,Teneobio Inc ,Children Oncology Group Study ,Administration In Adult Patients ,American Society ,Annual Meeting ,Presentation Times ,World Assessment ,Treatment Patterns ,Retrospective Cohort ,Poster Presentation ,Proteasome Inhibitor ,Exposed Relapsed ,Refractory Multiple Myeloma ,Multinational Assessment ,Acute Myeloid Leukemia ,Sponsored Abstracts ,Children With High Risk First Relapse ,B Cell Precursor Acute Lymphoblastic Leukemia ,Controlled Phase ,Indolent Non Hodgkin ,Measurable Residual Disease ,Sponsored Studies ,Results From ,Sequential Blinatumomab ,Randomized Phase ,Post Reinduction Therapy ,Low Risk ,First Relapse ,B Acute Lymphoblastic Leukemia ,Young Adults ,Oncology Group Study ,Oral Presentation ,Refractory Acute Lymphoblastic Leukemia ,Autologous Transplantation ,Adapted Consolidation ,Final Primary Endpoint Analysis ,Autologous Hematopoietic Cell Transplantation ,Multiple Myeloma Treated ,Romiplostim Use Connected ,Adult Patients ,Newly Diagnosed ,Persistent Immune Thrombocytopenia ,Subgroup Analysis ,Among Patients ,Hematologic Malignancies ,Solid Tumors ,Potential Impact ,Dosing Tolerance ,Facilitate Use ,Nplate Self Administration ,Romiplostim Dose ,Platelet Response Guided Titration ,Support Use ,Less Than ,From Diagnosis ,Investigator Sponsored Studies ,Young Adult Primary Immune Thrombocytopenia ,Independent Data Monitoring Committee ,Pediatric Investigation Plan ,Release Syndrome ,Lysis Syndrome ,Febrile Neutropenia ,Use Machines ,Liver Enzymes ,Serious Adverse Reactions ,Pediatric Patients ,Benzyl Alcohol Preservative ,United Arab ,Important Safety ,New York Heart Association Class ,Tumor Lysis Syndrome ,Respiratory Distress Syndrome ,Multifocal Leukoencephalopathy ,Serious Toxicities ,Newly Diagnosed Transplant Ineligible ,Myelodysplastic Syndromes ,Acute Myelogenous ,Abdominal Pain ,Shoulder Pain ,Prescribing Information ,Dow Jones Industrial Average ,Best Workplaces ,Great Place ,Five Prime Therapeutics ,Cancer Statistics ,Mortality Worldwide ,